A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4

被引：0

作者：

Janjigian, Y. Y. ^{[1
]}

Lloyd, C. ^{[2
]}

de Giorgio-Miller, V. G. ^{[3
]}

Chang, Y-T. ^{[4
]}

Lee, J. ^{[5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] AstraZeneca, Clin Dev Dept, New York, NY USA

[3] AstraZeneca, Clin Dev Dept, Cambridge, England

[4] AstraZeneca, Oncol R&D, Oncol Biometr, Late Stage Dev, Gaithersburg, MD USA

[5] Sungkyunkwan Univ, Div Hem Oncol, Samsung Med Ctr, Seoul, South Korea

来源：

关键词：

D O I：

10.1016/j.annonc.2024.10.282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

264TiP

引用

页码：S1502 / S1503

页数：2